Bile acid binding proteins in hepatocellular membranes of newborn and adult rats. Identification of transport proteins with azidobenzamidotauro[14C]cholate ([14C]ABATC).
Neonatal hepatocytes are less active in uptake of bile acids than are mature hepatocytes. This phenomenon has been further investigated by transport studies with azidobenzamidotaurocholate (ABATC). Taurocholate, cholate and the photolabile ABATC were taken up by liver cells of adult rats by a sodium-dependent and by an additional sodium-independent mechanism. In the dark, ABATC inhibited the uptake of taurocholate and cholate. Taurocholate decreased the transport of ABATC in a competitive manner, both in the presence and absence of sodium. In neonatal hepatocytes the Vmax for taurocholate and for ABATC was similar but was lower than in mature liver cells. In contrast, the Km was similar for neonatal and mature hepatocytes. For identification of binding proteins in both kinds of cells ABATC was photolysed after preincubation with isolated hepatocytes. Under our experimental conditions (single ultraviolet flash) about 80% of the azido groups was converted to nitrene. The covalently binding nitrene derivative inhibited bile salt transport irreversibly. Photolabeling of intact hepatocytes or of isolated plasma membranes with ABATC resulted in radioindication of membrane proteins with 67, 60, 54, 50 and 43 kDa in mature plasma membranes but of proteins with masses of 67, 54, 43 and 37 kDa in neonatal basolateral membranes. The 50 kDa protein in largely lacking in membranes of 9-day-old rats. The process of photolabeling itself was sodium-independent when isolated cells were treated with ABATC. In contrast, the degree of labeling of intact hepatocytes was markedly reduced in the absence of sodium and chloride. 100-fold molar excess of taurocholate, benzamidotaurocholate (BATC), phalloidin or cyclosomatostatin protected isolated plasma membranes against coupling of ABATC. Photolabeling of hepatoma cells known to be deficient in bile salt transport did not result in radiomodification of membrane proteins.
Ziegler
K
K
Institut für Pharmakologie und Toxikologie, Justus Liebig Universität Giessen, F.R.G.
Frimmer
M
M
Müllner
S
S
Fasold
H
H
D000345:Affinity Labels / Q000494:pharmacology*; D000818:Animals; D000831:Animals, Newborn; D001386:Azides / Q000494:pharmacology*; D001647:Bile Acids and Salts / Q000378:metabolism*; D001692:Biological Transport; D002352:Carrier Proteins / Q000378:metabolism*; D002462:Cell Membrane / Q000378:metabolism*; D019826:Cholic Acid; D002793:Cholic Acids / Q000378:metabolism; D006913:Hydroxysteroid Dehydrogenases; D007700:Kinetics; D008099:Liver / Q000378:metabolism*; D008297:Male; D008562:Membrane Glycoproteins; D051381:Rats; D011919:Rats, Inbred Strains; D012964:Sodium / Q000494:pharmacology; D013656:Taurocholic Acid / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology; D045002:3-alpha-Hydroxysteroid Dehydrogenase (B-Specific)
D000345:Affinity Labels; D001386:Azides; D001647:Bile Acids and Salts; D002352:Carrier Proteins; D019826:Cholic Acid; D002793:Cholic Acids; D006913:Hydroxysteroid Dehydrogenases; D008562:Membrane Glycoproteins; D012964:Sodium; D013656:Taurocholic Acid; C037643:bile acid binding proteins; C059201:azidobenzamidotaurocholate; C435496:AKR1C2 protein, human; D045002:3-alpha-Hydroxysteroid Dehydrogenase (B-Specific)